Home
>
US Stocks
>
Brooklyn ImmunoTherapeutics Inc
Brooklyn ImmunoTherapeutics Inc
BTX

Brooklyn ImmunoTherapeutics Inc (BTX)

$2.7411.04%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$2.98
Today Low/High$2.74 / $3
52 Week Low/High$2.89 / $80.67
Market Cap-

Company Details

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
OrganisationBrooklyn ImmunoTherapeutics Inc
Employees136
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Brooklyn ImmunoTherapeutics Inc (BTX) share price today?

Can Indians buy Brooklyn ImmunoTherapeutics Inc (BTX) shares?

How can I buy Brooklyn ImmunoTherapeutics Inc (BTX) shares from India?

Can Fractional shares of Brooklyn ImmunoTherapeutics Inc (BTX) be purchased?

What are the documents required to start investing in Brooklyn ImmunoTherapeutics Inc (BTX) stocks?